MicroPort NeuroTech™ APOLLO™ Intracranial Arterial Stent System Completed First Implantation in Brazil

Brasilia, Brazil, 19 August 2022 — MicroPort Neurotech Limited (“MicroPort NeuroTech™”), recently announced that its independently developed APOLLO™ Intracranial Arterial Stent System (“APOLLO™”) has been implanted in a patient in Brazil, which marks its first application in the country as well as in any overseas market outside China.

The patient was a 62-year-old female who presented with recurrent episodes of vertigo over a two-month period, unusual sensation in her left limbs, and lapses of consciousness. Considering the degree of atherosclerotic stenosis of the diseased vessel, Dr Bruno de Souza Mendes Parente decided to use the APOLLO™ stent, which provides a strong radial force. The successful implantation was performed by Dr Bruno de Souza Mendes Parente and his team at the Hospital Brasilia Águas Claras, Brazil. The patient's vertigo symptoms improved significantly after the implantation, and a post-operative physical examination demonstrated favorable results. The excellent pushability, the easy-to-use rapid exchange system, and the great radial strength of APOLLO™ were highly valued by the surgery team, and its clinical performance was also fully recognized.

The APOLLO™ Intracranial Arterial Stent System, which was approved for marketing in China in 2004, is designed to restore blood flow to the lesion and dilate the stenotic vessel through a minimally invasive approach. Such interventions have become an effective treatment for intracranial artery stenosis because of its safety, reliability, minimal damage, and rapid efficacy.

The clinical implantation of APOLLO™ in Brazil is the first time it enters an overseas market. This means the ischemic products of MicroPort NeuroTech™ have been further recognized by the overseas market. In the future, MicroPort NeuroTech™ will continue to strengthen in-depth cooperation with global clinical experts and provide more patients worldwide with better and more inclusive medical solutions for total stroke resolution.

About MicroPort NeuroTech™

Founded in Shanghai in 2012, MicroPort NeuroTech Limited (“MicroPort NeuroTech™”, stock code: 02172.HK), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK), is a pioneer and largest Chinese company in the neuro-interventional medical device industry in China, dedicated to providing innovative solutions for physicians and patients. MicroPort NeuroTech™ has gradually entered the top 10 countries and regions for the number of neuro-interventional surgeries, including the United States, Europe, South Korea and Brazil. In the future, MicroPort NeuroTech™ will invest more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro-interventions solutions for physicians and patients.

More information is available at www.medneurotech.com.